Aspira Women’s Health (NASDAQ:AWH) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Aspira Women’s Health (NASDAQ:AWH) from a sell rating to a hold rating in a report published on Wednesday.

Aspira Women’s Health Stock Down 3.6 %

NASDAQ AWH opened at $1.06 on Wednesday. The firm has a market cap of $17.02 million, a P/E ratio of -0.73 and a beta of 1.54. Aspira Women’s Health has a 52-week low of $0.86 and a 52-week high of $6.75. The business’s 50-day moving average price is $1.39 and its 200 day moving average price is $2.76.

Aspira Women’s Health (NASDAQ:AWH) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. The company had revenue of $2.42 million for the quarter, compared to analyst estimates of $2.60 million. During the same period in the previous year, the business posted ($0.28) earnings per share. As a group, analysts anticipate that Aspira Women’s Health will post -1.29 earnings per share for the current year.

Institutional Investors Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. Quantum Private Wealth LLC increased its stake in Aspira Women’s Health Inc. (NASDAQ:AWH) by 76.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,156 shares of the company’s stock after purchasing an additional 21,788 shares during the quarter. Quantum Private Wealth LLC owned 0.49% of Aspira Women’s Health worth $205,000 at the end of the most recent quarter. 12.19% of the stock is owned by hedge funds and other institutional investors.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.